Simon Piggott
Overview
Explore the profile of Simon Piggott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Piggott L, Piggott S, Kelly M
BMC Med Educ
. 2024 Oct;
24(1):1154.
PMID: 39415238
Telehealth is defined as the provision of health care services over a distance. Major health systems, including outpatient clinics and check-ups alike, turned to telehealth and teleconsultation amid the COVID19...
2.
Geller D, Nasr S, Piggott S, He E, Angyalosi G, Higgins M
Respir Care
. 2013 Aug;
59(3):388-98.
PMID: 23983274
Background: Tobramycin powder for inhalation (TIP) is a drug-device combination designed to reduce treatment time and improve ease of use compared with tobramycin inhalation solution (TIS) in cystic fibrosis (CF)...
3.
Galeva I, Konstan M, Higgins M, Angyalosi G, Brockhaus F, Piggott S, et al.
Curr Med Res Opin
. 2013 May;
29(8):947-56.
PMID: 23672633
Background: Tobramycin inhalation powder (TIP) was reported to be effective in two Phase III studies in patients with cystic fibrosis (CF) chronically infected with Pseudomonas aeruginosa (Pa). The EDIT study...
4.
Vogelmeier C, Ramos-Barbon D, Jack D, Piggott S, Owen R, Higgins M, et al.
Respir Res
. 2010 Oct;
11:135.
PMID: 20920365
Background: Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β2-agonist for the treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind study compared the bronchodilator efficacy of indacaterol with that...
5.
Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R, et al.
BMC Pulm Med
. 2010 Mar;
10:11.
PMID: 20211002
Background: Indacaterol is a novel, once-daily (o.d.) inhaled, long-acting beta2-agonist in development for chronic obstructive pulmonary disease (COPD). This 12-week, double-blind study compared the efficacy, safety, and tolerability of indacaterol...